International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis
Фаза 4 – наблюдение след одобрението на пазара
Заболявания:
Allergic rhinoconjunctivitis
Спонсор: Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l.
Налично на:
БГ
Обобщение
Trial status: Authorised
Overall AR symptoms will be evaluated through the mean change of the T5CSS score measured at baseline (V1) and after 14 days (V3) of treatment by a participant’s e-diary
Кой може да участва
Age group: 0-17 years
Gender: Female, Male
Target enrollment: 70 participants
БГ
EN